<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27647">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746796</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4538-37</org_study_id>
    <nct_id>NCT02746796</nct_id>
  </id_info>
  <brief_title>Study of ONO-4538 in Gastric Cancer</brief_title>
  <official_title>ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in
      unresectable advanced or recurrent gastric cancer (including esophagogastric junction
      cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate
      the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur
      / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine +
      Oxaliplatin). In part 2, the investigator or the subinvestigator will choose a chemotherapy
      (SOX or CapeOX therapy), taking into account the condition of each subject. Part 2 is
      planned to evaluate the efficacy and safety of ONO-4538 + chemotherapy in comparison with
      placebo + chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (central assessment by IRRC) (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 48 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (assessment by the site investigator)(only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in the sum of diameters of target lesions (only Part 2)</measure>
    <time_frame>Up to study completion (estimated time frame: 54 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of adverse events, serious adverse events</measure>
    <time_frame>Up to 28 days from last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of laboratory abnormalities</measure>
    <time_frame>Up to 28 days from last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>ONO-4538 + SOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-4538 + CapeOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-4538 + chemotherapy group (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Chemotherapy group (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.
Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.
Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4538</intervention_name>
    <arm_group_label>ONO-4538 + SOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + CapeOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + chemotherapy group (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>ONO-4538 + SOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + CapeOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + chemotherapy group (Part 2)</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy group (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur- Gimeracil-Oteracil potassium</intervention_name>
    <arm_group_label>ONO-4538 + SOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + chemotherapy group (Part 2)</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy group (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>ONO-4538 + CapeOX Therapy Cohort (Part 1)</arm_group_label>
    <arm_group_label>ONO-4538 + chemotherapy group (Part 2)</arm_group_label>
    <arm_group_label>Placebo + Chemotherapy group (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Chemotherapy group (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable advanced or recurrent gastric cancer (including
             esophagogastric junction cancer) that has not been treated with the first-line
             therapy with systemic antitumor agents for advanced or recurrent gastric cancer
             (including esophagogastric junction cancer)

          -  Have measurable lesions as defined in RECIST Guideline Version 1.1

          -  ECOG PS score 0 or 1

          -  Have a life expectancy of at least 3 months

        Exclusion Criteria:

          -  Have multiple cancers

          -  Have a current or past history of severe hypersensitivity to any other antibody
             products

          -  Patients with any metastasis in the brain or meninx that is symptomatic or requires
             treatment

          -  Patients with active, known or suspected autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsunobu Tanimoto</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ono Pharmaceutical Co. Ltd Corporate Communications</last_name>
    <email>y.tani@ono.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiba Clinical Site</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu Clinical Site</name>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido Clinical Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hyogo Clinical Site</name>
      <address>
        <city>Akashi-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kanagawa Clinical Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Clinical Site</name>
      <address>
        <city>Ikoma-shi</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site</name>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical Site</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Site</name>
      <address>
        <city>Koutou-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gyeonggi-Do Clinical Site</name>
      <address>
        <city>Gyeonggi-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jeollabuk-do Clinical Site</name>
      <address>
        <city>Jeollabuk-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Clinical Site 1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Clinical Site 2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul Clinical Site 3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Clinical Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
